ERG and posterior cortical atrophy: Here we have also demonstrated the efficacy of targeting ERG with SSOs in vivo using xenograft models and ex vivo using patient-derived PCa tumour samples, supporting the approach of targeting an oncogene with SSOs, as others have also previously shown.42,43 Mouse xenograft models using the ERG-positive MG63 cell line exhibited reduced tumour growth upon systemic E43′ SSO treatment, accompanied by reduced ERG protein levels in treated tumours harvested from the mice at the study’s conclusion.